MannKind | MNKD - Selling And Administration Expenses


MannKind reported $54.08M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Adma Biologics USD 26.74M 6.55M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Insmed USD 247.26M 34.78M Mar/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
MacroGenics USD 9.71M 1.77M Mar/2026
MannKind USD 54.08M 4.33M Mar/2026
Merck USD 2.67B 180M Mar/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Novavax USD 25.53M 1.34M Dec/2025
Novo Nordisk DKK 2.86B 13.25B Jun/2025
Pfizer USD 2.92B 1.16B Mar/2026
Sanofi EUR 2.33B 419M Mar/2026
Xencor USD 82.12M 65.08M Mar/2026